Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2020 · 10-Q
Revenue$3.77M$3.77M+46.8% vs Q2 2019 Net Income$13.05K$13.05KN/M vs Q2 2019 EPS Diluted$0.00$0.00N/M vs Q2 2019 Gross Profit$1,149,798+603.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$91,415−89.1% Free Cash Flowderived-$401,239N/M Margins · derivedGross margin30.5%+24.1 pt vs Q2 2019
Operating margin2.0%+31.3 pt vs Q2 2019
Net margin0.3%+33.0 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 13, 2020 · 44 d after period end